Zealand Pharma
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
Press Release – No. 3 / 2025
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
Copenhagen, Denmark, February 13, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it will host a conference call on February 20, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2024.
Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. There will be a presentation followed by a Q&A session.
The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at https://edge.media-server.com/mmc/p/96nk8pep. To receive telephone dial-in information and a unique personal access PIN, please register at https://register.vevent.com/register/BI735075144114493ead489441f1d0740f. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investors section of Zealand Pharma’s website at https://www.zealandpharma.com/investors/events-presentations/.
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.
Contacts:
Adam Lange (Investors)
Investor Relations Officer
Email: alange@zealandpharma.com
Neshat Ahmadi (Investors)
Investor Relations Manager
Email: neahmadi@zealandpharma.com
Anna Krassowska, PhD (Media and Investors)
Vice President, Investor Relations & Corporate Communications
Email: akrassowska@zealandpharma.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Baltic Horizon Fund / Northern Horizon Capital9.5.2025 14:35:00 CEST | Press release
Baltic Horizon will hold an Investor Conference Webinar to introduce the results for Q1 2025
Standard Lithium9.5.2025 14:30:02 CEST | Press release
Standard Lithium Reports Fiscal First Quarter 2025 Results
Norsk Hydro9.5.2025 14:15:00 CEST | Press release
Norsk Hydro: Minutes from the Annual General Meeting 2025
Global Center on Adaptation9.5.2025 14:03:25 CEST | Press release
GCA Welcomes Denmark’s Ole Thonke to its Advisory Board
Nykredit Realkredit A/S9.5.2025 13:58:00 CEST | Pressemeddelelse
Ledende medarbejdere og disses nærtstående transaktioner - Nykredit Realkredit A/S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom